Spark Therapeutics Inc (NASDAQ:ONCE) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 3,782 call options on the stock. This is an increase of approximately 2,582% compared to the typical daily volume of 141 call options.

Spark Therapeutics (NASDAQ ONCE) opened at $45.21 on Friday. Spark Therapeutics has a fifty-two week low of $41.06 and a fifty-two week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. Spark Therapeutics’s quarterly revenue was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.07) earnings per share. analysts predict that Spark Therapeutics will post -7.6 earnings per share for the current year.

A number of brokerages have weighed in on ONCE. Goldman Sachs Group reaffirmed a “buy” rating and issued a $111.00 price target on shares of Spark Therapeutics in a research note on Friday, October 6th. BMO Capital Markets set a $89.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 10th. Cowen reaffirmed a “buy” rating and issued a $95.00 price target on shares of Spark Therapeutics in a research note on Tuesday, October 10th. Chardan Capital reaffirmed a “buy” rating and issued a $100.00 price target on shares of Spark Therapeutics in a research note on Friday, October 13th. Finally, Raymond James Financial began coverage on shares of Spark Therapeutics in a research note on Thursday, October 12th. They issued an “outperform” rating and a $96.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $76.19.

In related news, insider Daniel Faga sold 1,500 shares of Spark Therapeutics stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total transaction of $127,500.00. Following the transaction, the insider now owns 1,500 shares of the company’s stock, valued at approximately $127,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeffrey D. Marrazzo sold 20,000 shares of Spark Therapeutics stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $71.54, for a total transaction of $1,430,800.00. Following the transaction, the chief executive officer now directly owns 250,000 shares in the company, valued at approximately $17,885,000. The disclosure for this sale can be found here. Insiders have sold a total of 1,068,809 shares of company stock worth $89,809,385 in the last three months. 7.30% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. boosted its position in Spark Therapeutics by 11.6% during the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after purchasing an additional 213,520 shares during the period. Vanguard Group Inc. boosted its position in Spark Therapeutics by 5.3% during the second quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock worth $114,968,000 after purchasing an additional 96,803 shares during the period. JPMorgan Chase & Co. boosted its position in Spark Therapeutics by 15.0% during the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after purchasing an additional 241,016 shares during the period. Janus Henderson Group PLC boosted its position in Spark Therapeutics by 46.4% during the third quarter. Janus Henderson Group PLC now owns 756,088 shares of the biotechnology company’s stock worth $67,413,000 after purchasing an additional 239,723 shares during the period. Finally, Orbimed Advisors LLC bought a new position in Spark Therapeutics during the third quarter worth $38,340,000. Institutional investors and hedge funds own 94.94% of the company’s stock.

WARNING: “Traders Buy High Volume of Spark Therapeutics Call Options (ONCE)” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/15/traders-buy-high-volume-of-spark-therapeutics-call-options-once.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.